Literature DB >> 21246384

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.

Kazuaki Chayama1, C Nelson Hayes, Kentaro Yoshioka, Hisataka Moriwaki, Takashi Okanoue, Shotaro Sakisaka, Tetsuo Takehara, Makoto Oketani, Joji Toyota, Namiki Izumi, Yoichi Hiasa, Akihiro Matsumoto, Hideyuki Nomura, Masataka Seike, Yoshiyuki Ueno, Hiroshi Yotsuyanagi, Hiromitsu Kumada.   

Abstract

BACKGROUND: Treatment of genotype 1b chronic hepatitis C virus (HCV) infection has been improved by extending peg-interferon plus ribavirin combination therapy to 72 weeks, but predictive factors are needed to identify those patients who are likely to respond to long-term therapy.
METHODS: We analyzed amino acid (aa) substitutions in the core protein and the interferon sensitivity determining region (ISDR) of nonstructural protein (NS) 5A in 840 genotype 1b chronic hepatitis C patients with high viral load. We used logistic regression and classification and regression tree (CART) analysis to identify predictive factors for sustained virological response (SVR) for patients undergoing 72 weeks of treatment.
RESULTS: When patients were separately analyzed by treatment duration using multivariate logistic regression, several factors, including sex, age, viral load, and core aa70 and ISDR substitutions (P = 0.0003, P = 0.02, P = 0.01, P = 0.0001, and P = 0.0004, respectively) were significant predictive factors for SVR with 48 weeks of treatment, whereas age, previous interferon treatment history, and ISDR substitutions (P = 0.03, P = 0.01, and P = 0.02, respectively) were the only significant predictive factors with 72 weeks of treatment. Using CART analysis, a decision tree was generated that identified age, cholesterol, sex, treatment length, and aa70 and ISDR substitutions as the most important predictive factors. The CART model had a sensitivity of 69.2% and specificity of 60%, with a positive predictive value of 68.4%.
CONCLUSIONS: Complementary statistical and data mining approaches were used to identify a subgroup of patients likely to benefit from 72 weeks of therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21246384     DOI: 10.1007/s00535-010-0358-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  38 in total

1.  Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

Authors:  Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Sachiyo Watahiki; Junko Sato; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2006-01       Impact factor: 2.327

2.  Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.

Authors:  Maria Buti; Yoav Lurie; Natalia G Zakharova; Natalia P Blokhina; Andrzej Horban; Gerlinde Teuber; Christoph Sarrazin; Ligita Balciuniene; Saya V Feinman; Rab Faruqi; Lisa D Pedicone; Rafael Esteban
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

3.  Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype.

Authors:  K Chayama; F Suzuki; A Tsubota; N Akuta; T Someya; M Kobayashi; Y Arase; S Saitoh; Y Suzuki; K Ikeda; H Kumada
Journal:  J Virol Methods       Date:  2001-06       Impact factor: 2.014

4.  Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.

Authors:  Harald Farnik; Christian M Lange; Christoph Sarrazin; Bernd Kronenberger; Stefan Zeuzem; Eva Herrmann
Journal:  Clin Gastroenterol Hepatol       Date:  2010-06-30       Impact factor: 11.382

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.

Authors:  Sumio Watanabe; Nobuyuki Enomoto; Kazuhiko Koike; Namiki Izumi; Hajime Takikawa; Etsuko Hashimoto; Fuminori Moriyasu; Hiromitsu Kumada; Michio Imawari
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

7.  Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis.

Authors:  Salvador Augustin; Laura Muntaner; José T Altamirano; Antonio González; Esteban Saperas; Joan Dot; Monder Abu-Suboh; Josep R Armengol; Joan R Malagelada; Rafael Esteban; Jaime Guardia; Joan Genescà
Journal:  Clin Gastroenterol Hepatol       Date:  2009-08-21       Impact factor: 11.382

8.  Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Authors:  Donald M Jensen; Patrick Marcellin; Bradley Freilich; Pietro Andreone; Adrian Di Bisceglie; Carlos E Brandão-Mello; K Rajender Reddy; Antonio Craxi; Antonio Olveira Martin; Gerlinde Teuber; Diethelm Messinger; James A Thommes; Andreas Tietz
Journal:  Ann Intern Med       Date:  2009-04-21       Impact factor: 25.391

9.  A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.

Authors:  Masayuki Kurosaki; Kotaro Matsunaga; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Yutaka Yasui; Nobuharu Tamaki; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Hiroki Ikeda; Jun Itakura; Yuka Takahashi; Yasuhiro Asahina; Megumu Higaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Hepatol Res       Date:  2010-01-11       Impact factor: 4.288

10.  Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.

Authors:  Ahmed El-Shamy; Mikiko Sasayama; Motoko Nagano-Fujii; Noriko Sasase; Susumu Imoto; Soo Ryang Kim; Hak Hotta
Journal:  Microbiol Immunol       Date:  2007       Impact factor: 1.955

View more
  3 in total

1.  The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.

Authors:  Toshiki Kan; Senju Hashimoto; Naoto Kawabe; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Kazunori Nakaoka; Masashi Ohki; Yuka Takagawa; Takamitsu Kurashita; Tomoki Takamura; Kentaro Yoshioka
Journal:  J Gastroenterol       Date:  2015-04-24       Impact factor: 7.527

2.  Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia.

Authors:  Sabino Russi; Domenico Sansonno; Maria Addolorata Mariggiò; Angela Vinella; Fabio Pavone; Gianfranco Lauletta; Silvia Sansonno; Franco Dammacco
Journal:  Arthritis Res Ther       Date:  2014-03-18       Impact factor: 5.156

Review 3.  HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.

Authors:  Kazuaki Chayama; C Nelson Hayes
Journal:  Viruses       Date:  2015-10-13       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.